This study reported treatment outcomes of 52 patients (62 lesions) treated with proton SBRT. Fractionation varied by indication and site with a median of 5 fractions and median fractional dose of 8 Gy. This study reported that proton-based SBRT can achieve dosimetric goals required by major clinical photon trials. There was no new grade 3 or greater toxicity during treatment. Comparing pretreatment to end of treatment timepoints, there was a significant improvement in patient reported outcomes, measured by the mean EQ-5D5L visual analogue score (VAS) (p = 0.014), and no significant change measured by the mean MD Anderson Symptom Inventory (MDASI) scores.